Home › Funds › RTW INVESTMENTS, LP › PTGX
RTW INVESTMENTS, LP position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
RTW INVESTMENTS, LP reported holding 5,061,175 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$713.1M, representing 7.20% of its reported portfolio and ranking #1 among its reported holdings. RTW INVESTMENTS, LP has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RTW INVESTMENTS, LP's PTGX position evolved
RTW INVESTMENTS, LP first disclosed a stake in PTGX in Q3 2023 at 5,415,514 shares (US$90.3M). The position peaked in Q3 2026 at 5,061,175 shares, worth US$713.1M. Across 13 filings, RTW INVESTMENTS, LP increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 5,061,175 shares valued at US$713.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.42M | $90.33M | New |
| Q4 2023 | 5.32M | $121.88M | Reduce |
| Q1 2024 | 5.32M | $153.78M | Hold |
| Q2 2024 | 5.29M | $183.17M | Reduce |
| Q3 2024 | 5.43M | $244.18M | Add |
| Q4 2024 | 5.50M | $212.24M | Add |
| Q1 2025 | 5.72M | $276.59M | Add |
| Q2 2025 | 5.76M | $318.15M | Add |
| Q3 2025 | 5.76M | $382.39M | Hold |
| Q4 2025 | 5.06M | $441.86M | Reduce |
| Q1 2026 | 5.06M | $533.22M | Hold |
| Q2 2026 | 5.06M | $620.40M | Hold |
| Q3 2026 | 5.06M | $713.07M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in PTGX — the largest reported positions include FARALLON CAPITAL MANAGEMENT, L.L.C. (US$907.0M), Farallon Capital Management (US$778.2M), JOHNSON & JOHNSON (US$345.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.44M sh · $907.04M · Q3 2026
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- JOHNSON & JOHNSON 2.45M sh · $345.07M · Q3 2026
- Woodline Partners LP 1.41M sh · $198.59M · Q3 2026
- ADAR1 Capital Management, LLC 951.40K sh · $134.04M · Q3 2026
- Hood River Capital Management LLC 893.48K sh · $125.88M · Q3 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 676.82K sh · $95.36M · Q3 2026
- 683 Capital Management, LLC 255.00K sh · $35.93M · Q3 2026
- Eagle Health Investments LP 248.32K sh · $34.99M · Q3 2026
More on RTW INVESTMENTS, LP
FAQ
How long has RTW INVESTMENTS, LP held PTGX?
RTW INVESTMENTS, LP has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RTW INVESTMENTS, LP's current position in PTGX?
As of Q3 2026, RTW INVESTMENTS, LP holds 5.06M shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $713.07M, representing 7.20% of its reported portfolio and ranking #1.
Has RTW INVESTMENTS, LP been buying or selling PTGX?
In the latest 13F filing (Q3 2026), RTW INVESTMENTS, LP held unchanged its position in PTGX. The position peaked in Q3 2026 at 5.06M shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include FARALLON CAPITAL MANAGEMENT, L.L.C., Farallon Capital Management, JOHNSON & JOHNSON, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.